Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891085 | 0.87 | FOLH1 (0.42) | FOLH1ALDH1A1LMNACYSLTR2CYSLTR1 | |
| SCHEMBL891262 | 0.80 | FOLH1 (0.39) | FOLH1ALDH1A1LMNAADRB2 | |
| SCHEMBL1901916 | 0.75 | FOLH1 (0.46) | FOLH1ALDH1A1LMNA | |
| SCHEMBL2453232 | 0.73 | LIPG (0.51) | ALDH1A1LMNACYSLTR2CYSLTR1 | |
| SCHEMBL11570752 | 0.72 | LIPG (0.54) | ALDH1A1LMNACYSLTR2CYSLTR1 | |
| SCHEMBL11569404 | 0.72 | LIPG (0.54) | ALDH1A1LMNACYSLTR2CYSLTR1 | |
| SCHEMBL9456266 | 0.72 | LIPG (0.54) | ALDH1A1LMNACYSLTR2CYSLTR1 | |
| SCHEMBL18519295 | 0.72 | LIPG (0.54) | ALDH1A1LMNACYSLTR2CYSLTR1 | |
| SCHEMBL9456049 | 0.72 | LIPG (0.54) | ALDH1A1LMNACYSLTR2CYSLTR1 | |
| SCHEMBL28468212 | 0.72 | LIPG (0.54) | ALDH1A1LMNACYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710091-B2 | Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug | IPSEN PHARMA S.A.S. (FR) | 2014-04-29 | — | — | US | disclosed |
| US-20120083514-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083514-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | MKI67, CCND2, CCND1 | FOLH1 4446/4885ALDH1A1 759/4885LMNA 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.